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Humanizing the mdx mouse model of DMD: the long and the
short of it
Nora Yucel1, Alex C. Chang1, John W. Day2, Nadia Rosenthal3 and Helen M. Blau1
Duchenne muscular dystrophy (DMD) is a common fatal heritable myopathy, with cardiorespiratory failure occurring by the third
decade of life. There is no specific treatment for DMD cardiomyopathy, in large part due to a lack of understanding of the
mechanisms underlying the cardiac failure. Mdx mice, which have the same dystrophin mutation as human patients, are of limited
use, as they do not develop early dilated cardiomyopathy as seen in patients. Here we summarize the usefulness of the various
commonly used DMD mouse models, highlight a model with shortened telomeres like humans, and identify directions that warrant
further investigation.
npj Regenerative Medicine  (2018) 3:4 ; doi:10.1038/s41536-018-0045-4
INTRODUCTION
Since 1986, we have known the genetic cause of the devastating
skeletal muscle disorder, Duchenne muscular dystrophy (DMD)
due largely to the efforts of Lou Kunkel and colleagues who
undertook the characterization of one of the largest genes in the
genome, a formidable task at the time.1 Despite the identification
of dystrophin as the cause, nearly 30 years later there is still no
long-term cure for the disease. As with many genetic disorders in
humans, a major obstacle has been generating an animal model
that manifests all aspects of the disease. For decades, the majority
of DMD research has been conducted using themdx model, which
has a mutation in the dystrophin gene itself like DMD patients. A
conundrum has been that although mdx mice lack dystrophin
expression and exhibit chronic degeneration and regeneration of
their myofibers, they do not manifest a number of symptoms of
DMD. In particular, mdx mice do not exhibit dilated cardiomyo-
pathy (DCM) or a shortened lifespan. To overcome this limitation,
a number of double knockout mouse models have been
developed that combine the dystrophin mutation of the mdx
mouse with additional mutations. These second hits are in a
variety of genes that have roles in myogenesis and muscle
function. Double knockout mouse models exhibit exacerbated
disease phenotypes, but to variable degrees. In particular,
although these models recapitulate the human DMD skeletal
muscle phenotype better than the mdx mouse, the cardiac
phenotype is not fully recapitulated. Nonetheless, these models
have been instrumental in augmenting our understanding of the
molecular components and mechanisms of disease progression. In
this review we discuss the pathology of DMD, describe the major
mouse models that have been developed and their molecular
basis, and the relevance of these models to the human disease.
The “long and the short of it” is that in a comparison to existing
mouse models, the mdx4cv/mTRG2 model with “humanized”
somewhat shortened telomeres currently most closely approx-
imates human DMD and will advance tests of therapeutic
strategies. We wish to thank the Jackson Laboratory for making
these mice available at a reduced cost.
CLINICAL PARAMETERS OF DMD
DMD is a devastating X-linked genetic disorder that affects 1 in
5000 boys.2 An incurable disease, DMD is characterized by
progressive muscle degeneration due to loss of the key muscle
protein, dystrophin. Dystrophin is a crucial component of the
dystrophin-associated protein complex, which connects the
sarcolemma and extracellular matrix to the actin cytoskeleton
within skeletal myofibers and cardiomyocytes. This complex is
composed of a number of proteins, which are summarized in Fig.
1. Deletion of dystrophin results in mechanical instability causing
myofibers to weaken and eventually break during contraction. In-
frame mutations leading to truncation of the protein results in the
much milder disease, Becker muscular dystrophy (BMD).3 Patients
with DMD first display skeletal muscle weakness in early
childhood, which progresses rapidly to loss of muscle mass, spinal
curvature known as kyphosis, paralysis and ultimately death from
cardiorespiratory failure before 30 years of age.
Skeletal muscle pathogenesis
Skeletal muscle decline is the first symptom to appear in DMD,
arising by the time patients begin to learn to walk, around 3–5
years of age.4 Early symptoms include fatigue, difficulty standing
resulting in the Gower Maneuver, difficulty walking, running and
jumping, as well as frequent falls and a characteristic ‘waddling’ or
Trendelenburg gait.5 Official diagnoses are made by testing blood
for levels of elevated creatine phosphokinase, and by genetic
testing for mutations in the dystrophin gene. Skeletal muscles of
DMD patients also develop muscle hypertrophy, particularly of the
calf, evidence of focal necrotic myofibers, abnormal variation in
myofiber diameter, increased fat deposition and fibrosis, as well as
lack of dystrophin staining in immunohistological sections.6
Measures of DMD disease primarily follow skeletal muscle
symptoms, which are progressive throughout the teenage years.
Around the age of 12, patients lose the ability to walk, develop
kyphosis and have to use a wheelchair. Clinical endpoints include
the 6-min walk test and distance to assess ambulatory function,
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timed function test to measure time taken to stand from a supine
position, and myometry to evaluate strength of upper and lower
extremities.7
Intellectual impairment
Some degree of intellectual impairment is observed in all patients.
About 20% of boys with DMD have an IQ of less than 70, with
more intellectual impairment observed in those with mutations in
the brain-specific dystrophin isoform.8 This form of dystrophin is
initiated between exons 62 and 63, contains only the cysteine-rich
and carboxyl-terminus domains, and is only 71 kD compared to
the 427 kD form expressed in muscle.9 Intellectual impairment is
greater in patients with deletion break-points distal to exon 30.
Unlike muscle and cardiac symptoms, however, intellectual
impairment has not been shown to be progressive.
Cardiac pathogenesis
Although skeletal muscle symptoms are considered the defining
characteristic of DMD, patients most commonly die of respiratory
or cardiac failure. With recent advances in respiratory support,
however, most DMD patients now succumb to the disease around
age 30 from to DCM.2,10 DMD patients develop DCM due to the
absence of dystrophin in cardiomyocytes, which is required for
contractile function. This leads to an influx of extracellular calcium,
triggering protease activation, cardiomyocyte death, tissue
necrosis, and inflammation, ultimately leading to accumulation
of fat and fibrosis.11,12 This process first affects the left ventricle
(LV), which is responsible for pumping blood to most of the body,
and is thicker and therefore experiences a greater workload.
Atrophic cardiomyocytes exhibit a loss of striations, vacuolization,
fragmentation, and nuclear degeneration.10,13 Functionally, atro-
phy and scarring leads to structural instability and hypokinesis of
the LV,14,15 ultimately progressing to general DCM.
Currently, electrocardiography (ECG), echocardiography (ECHO)
and cardiovascular magnetic resonance imaging (MRI) are used to
diagnose functional symptoms of DMD cardiomyopathy. Early
abnormalities are often first detectable by ECG, and precede
markers of overt cardiac disease; eventually all patients have
cardiac involvement. Because of limited exercise capability due to
muscle weakness, early cardiac symptoms are often undetected
despite cardiac dysfunction. However, ultrastructural aberrations
are apparent in cardiomyocytes from DMD patients with no or
sub-clinical evidence of cardiomyopathy. Analysis of endomyo-
cardial biopsies by electron microscopy of four DMD patients with
normal ECG exhibited increased fragmentation of mitochondria,
abnormal mitochondrial cristae, aberrant Z bands, dilation of the
sarcoplasmic reticulum, deposition of glycogen, and atypical
nuclei.16
However, a true natural history study of the progression of the
cardiac phenotype in DMD is precluded by a number of factors.
Hearts of DMD patients are under diminished workload as patients
lose the ability to walk and transition to using a wheelchair.
Furthermore, as a standard of care, DMD patients are often treated
with non-specific angiotensin converting enzyme inhibitors and/
or β-blockers prior to cardiac symptoms as a protective measure.17
Therefore, there is an unmet need to characterize the progression
of cardiac symptoms, as well as recapitulate the clinical endpoints
of the human disease in mouse models.
MOLECULAR PARAMETERS OF DMD
Dystrophin and its role in the DGC
Dystrophin is a critical component of the dystrophin–glycoprotein
complex, or DGC, which anchors the γ-actin filaments of the
intracellular cytoskeleton within the myofiber to the basal lamina
and extracellular matrix (Fig. 1). Dystrophin is a large, 427 kDa, rod-
shaped intracellular protein localized to the cytoplasmic face of
the sarcolemma in cardiac and skeletal muscle tissues.18–20 Full-
length dystrophin has 24 spectrin-like repeats, and consists of four
functional domains: (i) the N-terminal region which binds to F-
actin, (ii) the middle-rod domain, which contains an additional
actin-binding region as well as an nNOS binding site, (iii) the
cysteine-rich domain, and (iv) the C-terminal domain. Four shorter
nonmuscle isoforms are also expressed from the dystrophin gene
from downstream promoters, and share at least the cysteine-rich
and COOH-terminal domains with the full-length protein. Named
in accordance with their molecular weights, Dp260 (Dystrophin
protein of 260 kDa) is found in the outer plexiform layer of the
retina, Dp140 is detected in the kidney, retina, and brain, and
Dp116 is mainly expressed in Schwann cells in spinal cord. The
full-length dystrophin isoform found in cardiac and skeletal
muscle is denoted Dp427. The shortest isoform, Dp71 is broadly
expressed in cardiac muscle, retina, kidney, liver, lung and brain.
Mutations in these shorter isoforms contribute to the non-muscle
symptoms seen in DMD, as well as to non-muscle syndromes of
their own accord; however, it is the disruption of full-length
dystrophin that is the primary etiology of DMD.
Utrophin has a similar structure and function to dystrophin, but
lacks two spectrin-like repeats, as well as the critical nNOS-binding
site.21,22 It is primarily expressed in skeletal muscle during fetal
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Fig. 1 Components of the dystrophin-associated glycoprotein
complex. The dystrophin-associated glycoprotein complex (DGC)
and proteins that interact with DGC are depicted here. Extracellular,
membrane, cytoplasmic and nuclear components are shown. The
proteins targeted in double knockout mouse models of DMD, as
outlined in the text, are indicated: (1) Dystrophin (2) Utrophin (3) α-
Dystrobrevin (4) α7-Integrin (5) Myogenic differentiation factor 1
(Myod) (6) Glycans and (7) telomere length. The domains of
dystrophin are also indicated: (i) N-terminal domain (ii) middle
body domain, which includes the nNOS binding sites (iii) cysteine-
rich domain and (iv) C-terminal domain. In addition, DMD disease
modifiers not directly involved in the DGC but that are also targeted
in double knockout studies are also highlighted
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development in both mice and humans, and is down-regulated
before birth in normal muscle.23 In the absence of dystrophin,
utrophin is often up-regulated, but due to the functional
differences in the protein, it does not fully compensate for
dystrophin in human DMD.24
The dystrophin–glycoprotein complex (DGC) is crucial for
maintaining the structural integrity of the sarcolemma during
muscle contractions.25 Dystrophin interacts with the DGC through
the cysteine-rich and the C-terminal domains, and is responsible
for localization of the DGC to the sarcolemma. Without dystrophin
as an anchor, most of the proteins of the DGC are lost from the
sarcolemma, leading to both mechanical weakening and aberrant
cell signaling.
The DGC is comprised of transmembrane (β-dystroglycan, α-
sarcoglycan, β-sarcoglycan, γ-sarcoglycan, and δ-sarcoglycan, and
sarcospan), intracellular (α1-syntrophin and β1-syntrophin, α-
dystrobrevin, and nNOS) and extracellular proteins (α-dystroglycan
and laminin-2), which provide both structural integrity and signal
transduction properties.26 Finally, glycosylation, or addition of
carbohydrate groups called glycans to transmembrane elements,
facilitates signaling to ligands in the extracellular matrix.
At the core of the DGC is the transmembrane protein
dystroglycan, which acts as a direct link between the extracellular
matrix and the sarcolemma. It is comprised of α and β subunits,
which are spliced from the same transcript.27 The carboxyl-
terminal end of β-dystroglycan interacts with the cysteine-rich
domain (Domain 3) of dystrophin, while the amino-terminus
interacts with the extracellular α-Dystroglycan subunit. α-Dystro-
glycan in turn links the extracellular matrix, acting as a receptor for
laminin-2. On the intracellular face, syntrophin proteins α1 and β1
bind to carboxyl-terminal end of dystrophin, and are critical for
signal transduction. α1-syntrophin has an nNOS-binding site. The
protein α-dystrobrevin, which binds to both syntrophins and
dystrophin,28–30 is a substrate for tyrosine kinases,31 and is
required for proper localization of nNOS to the sarcolemma.30
Loss of dystrophin in both DMD patients and DMD animal models
causes nNOS to mislocalize to the cytosol.32
The sarcoglycan complex provides additional mechanical
support to the DGC and sarcolemma. This complex of transmem-
brane proteins is comprised of sarcoglycans α, β, γ and δ,33 as well
as sarcospan.34,35 Mutations that result in structural defects in any
of the sarcoglycans leads to destabilization of the entire complex,
weakening the sarcolemma and leading to a set of limb-girdle
muscular dystrophies called sarcoglycanopathies.36–38 δ-sarcogly-
can knockout mice develop cardiomyopathy due to disruption of
the sarcoglycan sarcospan complex in vascular smooth muscle.39
Integrins
In addition to the DGC, integrins are critical for the interactions
between the cytoskeleton of myofibers and the extracellular
matrix. Integrins are transmembrane glycoproteins that exist as
heterodimers consisting of α and β chains. They form a major
family of cell surface adhesion receptors that exist across cell
types, with 18 α and 8 β chains identified to-date. With the
exception of α6β4, all integrins link to the actin filaments in the
cytoskeleton.40 A number of integrin subunits are expressed in
skeletal muscle across myogenesis and development: α1, α3, α4, α5,
α6, α7, α9, αv, β1, and β3.
41,42 The α1, α3, α6, α7 and α9 integrin
subunits dimerize with β1 to form laminin-binding integrins. In
adult muscle, only α7β1 is found at the sarcolemma. Like the DGC,
α7β1 integrin is a laminin-2 receptor for skeletal and cardiac
muscle, and is upregulated upon terminal differentiation of
myotubes. Similarly, α7β1 integrin is critical for maintaining
stability of the myofiber sarcolemma, and can partially compen-
sate in this regard if the DGC is dysfunctional.43 In skeletal muscle
of both DMD patients and the mdx mouse, α7β1 integrin is up-
regulated to compensate for the lack of dystrophin, and the
resulting instability of the DGC.44
The myogenic program of transcriptional regulators
The physiological function of muscle is inherently contingent on
the proper implementation of the myogenic program, which
drives the differentiation of muscle stem cells (MuSCs), also known
as satellite cells, into fully formed myofibers during development
and regeneration. Muscle degeneration of patients with DMD is
due in part to exhaustion of MuSCs, which lose their stem cell
capacity due to continuous cycles of chronic injury and repair
caused by loss of dystrophin. Molecularly, MuSCs are defined by
the expression of the essential paired-box transcription factor
Pax7,45,46 as well as the absence of myogenic specialization factors
such as MyoD1 (Myogenic differentiation factor 1) and Myogenin.
Following injury, PAX7+ MuSCs become activated and expand.
These transiently amplifying progenitors express a series of
myogenic regulatory factors (MRFs), basic helix-loop-helix (bHLH)
transcription factors that up-regulate genes required for differ-
entiation into myofibers (Fig. 1). MYF5 (Myogenic Factor 5) is the
first to be upregulated, and the MYF5 protein acts as a chromatin
modifier of myogenic genes.47 MYF5 expression is followed by
MYOD1, a potent transcriptional activator of myogenesis48 that
shares many genomic targets with MYF5, and can rescue
myogenesis in the absence of MYF5.49 Because of their over-
lapping functions, knockout of either MYOD1 or MYF5 results in
no skeletal muscle defects,50 but MYOD/MYF5 double knockouts
lack expression of myogenic genes and any discernable formation
of myofibers.49 Both development, and adult muscle regeneration
is contingent on the synchronized action of these major myogenic
transcription factors.
CURRENT ANIMAL MODELS
Numerous mouse models have been developed to better under-
stand the basic biology of the disease. They have sought to
address the lack of a severe phenotype by combining the mdx
genotype with additional mutations. The skeletal muscle and
cardiac phenotypes, as well as lifespan of these models are
described below and are summarized in Table 1.
They have led to functional characterization of the proteins that
interact with dystrophin, identification of disease modifiers, and a
greater understanding of the molecular biology of DMD. However,
there has been a lack of animal models that recapitulate the
disease and enable a test of therapeutic strategies. As a result,
despite the robust methods for diagnosis and detailed character-
ization of disease progression, available therapies are still
palliative, minimizing symptoms rather than addressing the true
cause of the disease. This review summarizes the mouse models
that have forged our understanding of molecular mechanisms and
disease pathogenesis, and driven progress towards a cure for
DMD. In each case we describe the gene, the phenotype of the
single genetic knockout, then the phenotype of the double
knockout with mdx, and finally the human disease relevance of
the mutation. We suggest that to date, the mdx4cv/mTRG2 model
with telomeres that are shortened, i.e., “humanized”, appears to
most faithfully recapitulate both skeletal muscle and cardiovas-
cular features of human DMD.
Dystrophin (mdx, mdx2–5cv, mdx52, mdx βgeo, Dmd-null)
Most of studies in DMD have been conducted in mouse models
with mutations in dystrophin. The first mouse model of DMD was
the Dmdmdx (mdx) line, which arose spontaneously in a C57BL/
10ScSn colony.51 It was identified in a screen designed to discover
glycolytic enzyme activity mutants, and shown to have 3-fold
higher blood levels of pyruvate kinase activity.52 Molecular
analysis showed that this line carried a nonsense mutation in
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exon 23, resulting in an early termination codon and a truncated
protein.53,54 Most studies as well as the double knockout mouse
models described here utilize this mdx animal unless noted
otherwise. Like the human disease, mdx skeletal muscles exhibit
active myofiber necrosis, cellular infiltration, a wide range of
myofiber sizes and numerous centrally nucleated regenerating
myofibers. This phenotype is enhanced in the diaphragm, which
undergoes progressive degeneration and myofiber loss resulting
in an approximately 5-fold reduction in muscle isometric
strength.55 However, despite the absence of dystrophin in skeletal
and cardiac muscles, adult mdx mice do not exhibit the
pathogenic progression characteristic of human DMD. Necrosis
and regeneration in hind-limb muscles peaks around 3–4 weeks of
age, but plateaus thereafter.56,57 Severe muscle weakness, loss of
muscle weight, accumulation of fat and fibrosis do not appear
significantly until almost two years of age.58 Unlike patients,
cardiac functional defects are not apparent in young adult mdx
mice. Echocardiographic signs of cardiomyopathy do not appear
until about 10 months of age, while histological evidence of
interstitial cardiac fibrosis does not appear until about
17 months;59 however, infiltrating histiocytes and lymphocytes
suggest that matrix remodeling is ongoing.60 Interestingly, when
crossed onto other mouse backgrounds, a mild but significant
decrease in cardiac ejection fraction was observed, highlighting
the importance of genetic background.61 Notably, lifespan is not
significantly reduced in the mdx mouse model.
A number of alternative versions in different genetic back-
grounds have since been generated. The mdx2cv, mdx3cv, mdx4cv,
and mdx5cv lines were created in the C57BL/6 genetic background,
which shares a common origin with the C57BL/10 but is a more
commonly used strain. These models were created by treating
mice with N-ethyl-N-nitrosourea, a chemical mutagen.62 Each
strain carries a different point mutation.63 The mdx2cv mouse has a
point mutation at the splice acceptor site in intron 42, while the
mdx3cv mouse has a point mutation in the splice acceptor site of
intron 65. Increased preservation of muscle strength is observed in
the mdx3cv mouse due to expression of near full-length dystrophin
at ~5% of normal levels.64 Unlike the other mdxcv variants, the
mdx3cv mutation affects isoforms of dystrophin in other tissues,
and has been shown to exhibit non-muscle phenotypes such as
cognitive defects,65 abnormal electroretinogram66 and low
reproductive rate.67 The mdx4cv and mdx5cv models have a
nonsense mutation resulting in a premature stop codon in exon
53, and a point mutation resulting in a new splice site in exon 10,
respectively. Compared to the mdx mouse, the mdx4cv and mdx5cv
exhibit 10-fold fewer revertant myofibers, i.e. myofibers in which
dystrophin expression is spontaneously restored.68 As a whole,
however, these are few differences in the presentation of disease
phenotypes in the mdxcv models compared to the mdx mouse.
Alternative genetic models have been used to probe the role of
non-skeletal and cardiac isoforms of dystrophin. Unlike the mdx
and mdxcv lines, the mdx52, mdxβgeo and Dmd-null lines have
mutations that affect shorter isoforms of dystrophin found outside
heart and skeletal muscle. The mdx52 mouse was generated using
targeted deletion of exon 52 via replacement with a neomycin
cassette.69 In addition to loss of the heart and skeletal muscle
isoform of dystrophin, the mdx52 animal exhibits loss of the
shorter isoforms Dp260, which is expressed in the retina, and
Dp140, which is expressed in the brain and kidney. The location of
the deletion, exon 52, corresponds to the hot spot region between
exons 45–55 where about 70% of DMD patients have mutations.70
As such, these mouse models have been used for evaluating exon
skipping therapies.71 Compared to mdx animals, mdx52 mice have
fewer revertant fibers and abnormal electroretinograms similar to
DMD patients with mutations in that region system.72,73 The
mdxβgeo mouse (also called Dmdmdx-βgeo) was created via insertion
of a gene trap vector (ROSAβgeo) in exon 63 of Dmd.74 This
insertion leads to loss of cysteine rich and C-terminal domains,T
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resulting in disruption of all isoforms of dystrophin, as well as
tagging by β-galactosidase (LacZ reporter). In addition to skeletal
muscle and cardiac defects similar to the mdx animal, this line also
exhibits an abnormally dilated esophagus, and has been useful for
studying the role of dystrophin in development. Finally, the Dmd-
null mouse was created by deleting the entire Dmd genomic
region using the Cre-loxP.75 These animals have no expression of
dystrophin isoforms in any tissues, and do not have any revertant
fibers. Surprisingly, neither a cardiac phenotype nor premature
death were reported for these Dmd-null mice. In addition to
muscular defects, they also present behavioral abnormalities and
male sterility. Overall the mdx52, mdxβgeo and Dmd-null lines have
been instrumental in elucidating the roles of non-muscle
dystrophin isoforms. While they have been valuable for studying
the molecular signatures of human dystrophin mutations, these
alternative dystrophin mutation models are similar to the original
mdx mouse in regards to cardiac and skeletal muscle defects
which are far less severe than in DMD patients, and do not lead to
premature death.
Utrophin (mdx/Utrn−/−)
A dystrophin homolog, utrophin has very high amino acid
sequence similarity to dystrophin, and like dystrophin, links the
sarcolemma to the cytoskeleton. Unlike dystrophin, utrophin RNA
is expressed in a range of adult tissues besides the heart and
skeletal muscle, including brain, kidney, liver, lung, spleen and
stomach. The protein, which is normally down-regulated in
skeletal muscle after birth, accumulates at the sarcolemma of
the continuously regenerating mdx muscle.
The Utrn knockout mouse Utrntm1Ked (Utrn−/−) was generated by
an insertion of a neomycin cassette in exon 7 of the utrophin
gene, disrupting protein expression.76 Utrn−/− homozygotes have
overall normal appearance and behavior, and display only mild
abnormalities at neuromuscular junctions.76
The potential compensatory role of utrophin was assessed
through generation of double loss of function mutants. The mdx/
Utrn−/− double knockout mice have a severe disease phenotype.77
Whereas mdx single knockout mice do not exhibit signs of
dystrophic pathology until 3–4 weeks of age, diaphragms of mdx/
Utrn−/−mice exhibit necrosis as early as 6-days of age, with large
amounts of myofiber degeneration and regeneration apparent at
2-weeks of age. By 4–6 weeks of age, mdx/Utrn−/− mice exhibit
progressive weight loss, muscle weakness, kyphosis, abnormal gait
and joint contractures. Additionally, mdx/Utrn−/− mice develop
signs of cardiomyopathy, starting with cardiomyocyte membrane
damage and necrosis by 8–10 weeks of age.77 More recent
functional analyses have uncovered that these animals also
develop cardiac fibrosis, LV dilation, and reduced left ventricular
fractional shortening and ejection fraction as assessed by ECHO.78
Ultimately, mdx/Utrn−/− mice die prematurely at 20 weeks of age
due to respiratory failure. Notably, overexpression of either
truncated or full-length utrophin in mdx mice has been shown
to ameliorate phenotypic and histological muscle phenotypes.79–
81
The role of utrophin compensation has been shown to have
disease relevance in DMD patients. Regenerating myofibers in
both DMD and BMD patients show elevated levels of utrophin.82
In addition, some Duchenne patients have increased utrophin
expression.83 Underscoring the ability of utrophin to partially
compensate for dystrophin, such higher utrophin expression has
been correlated with decreased disease severity.84 However,
overall disease outcomes are unaffected, and symptoms in
patients with higher levels of utrophin progress at only a delayed
rate. Thus, it appears that while utrophin overexpression
functionally compensates for the skeletal muscle defects of
dystrophin deficiency in the mdx mouse, it does so to a lesser
degree in patients. Regardless, the mdx/Utrn−/− double knockout
mouse demonstrated that exacerbating DGC dysfunction results
in a humanized mouse skeletal muscle phenotype, but only
moderate cardiomyopathy.
α-Dystrobrevin (mdx/Dtna−/−)
The α-dystrobrevin protein binds to dystrophin, and is essential for
tyrosine kinase signal transduction as well as localization of nNOS
signaling to the sarcolemma. The single knockout DtnaTm1Jrs
(originally referred to as adbn) mouse was generated by insertion
of a neomycin resistance cassette replacing a 2.5 kb region
containing exon 3, resulting in a deletion of a muscle-specific
isoform of α-dystrobrevin.30
Single knockout, homozygous Dtna−/− mice develop normally
until 2 weeks of age, but develop a mild myopathy by one month
of age. Similar to the mdx mouse, the diaphragm is the most
severely affected skeletal muscle due to its constant workload. In
addition, Dtna−/− single knockouts show loss of localization of
nNOS to the skeletal muscle sarcolemma consistent with its role in
nNOS signaling as well as neuromuscular junction defects. Hearts
of Dtna−/− single knockouts also exhibit partial disease pheno-
types, including nuclear cell infiltration and necrosis, but do not
appear to be significantly hypertrophic or dilated.30 More recent
studies have shown that Dtna−/− mice also have highly increased
susceptibility to injury during cardiac stress induced by a chronic
high-dose isoproterenol stress test.85
The mdx/Dtna−/− double knockout mouse was developed to
determine the pathological role of the intracellular signaling
component of the DGC in DMD. Double knockout mdx/Dtna−/−
mice have aggravated skeletal muscle myopathy, although to a
lesser degree than mdx/Utrn−/− double knockouts, as well as
decreased lifespan of 8–10 months.30 Finally, mdx/Dtna−/− mice
develop moderate cardiomyopathy.
There is evidence for involvement of α-dystrobrevin in human
disease, including DMD. A missense mutation α-dystrobrevin was
linked to a Japanese family with a four-generation incidence of left
ventricular non compaction cardiomyopathy.86 Non-skeletal mus-
cle specific isoforms of the protein have also been linked to
Meniere’s disease, a chronic disorder of the inner ear.87 In DMD,
there is evidence of reduced levels of α-dystrobrevin at the
sarcolemma of patients.88 Reduced protein levels of α-dystrobre-
vin have also been associated with myopathies of patients with
normal dystrophin expression.89 However, these studies showed
no mutation in the α-dystrobrevin gene itself, suggesting an error
in splicing regulation. These studies demonstrate that α-dystro-
brevin function is critical for integrity of the myofiber sarcolemma.
α7-Integrin (mdx/α7−/−)
α7-integrin protein is highly expressed in skeletal, cardiac, and
smooth muscle. It is upregulated in the skeletal muscle of DMD
patients as well as in mdx mice.44 In addition, over-expression of
α7-integrin has been shown to improve mobility and extend life
span in the mdx/Utrn−/− double knockout mouse,90,91 suggesting
that α7-integrin may compensate for the absence of a functional
DGC.
Underscoring the importance of integrins to muscle function,
loss of α7-integrin alone causes a form of myopathy in single
knockout mice α7−/−.92 Animals were generated through disrup-
tion of exon 1, which inactivates all known splice variants of α7-
integrin. Homozygous α7−/− single knockout mice show embryo-
nic lethality with incomplete penetrance due to vascular defects.
Surviving animals exhibit normal muscle development, and are
viable and fertile, but develop myopathy soon after birth.
Centralized nuclei, myofiber necrosis and disruption of myotendi-
nous junctions are visible at 24 days of age. Myopathy and
myofiber degeneration is progressive, with differences in gait
visible at 100 days. In the diaphragm, histopathology shows
necrosis and hypertrophic myofibers, yet α7−/− knockouts do not
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develop gross respiratory defects. Similarly, cardiac defects in
these mice have not been observed.
The mdx/α7−/− double knockout mouse93 was generated to test
the role of the integrin protein complex in DMD. Like the DGC, this
complex provides a mechanical link between the cytoskeleton and
the extracellular matrix through laminin. In contrast to the
relatively mild defects of the single knockouts, double knockout
mdx/α7−/− mice show a significant dystrophic phenotype. Animals
exhibit progressive muscle wasting, and die 24–27 days after birth
from respiratory failure. At 20 days postnatal mdx/α7−/− hearts
develop signs of mild cardiomyopathy, including eosinophilic
cardiomyocytes, large necrotic areas in ventricular walls, cardio-
myocyte disarray, and accumulation of variable sizes of mitochon-
dria.93 Despite these histopathological defects, however, ECHO
reveals no functional defects, with no differences in cardiac
ventricular diameters, wall thickness or ejection fraction. The lack
of cardiac defects suggests that while α7-integrin may partially
compensate for skeletal muscle degeneration, such compensation
is not responsible for the increased severity of human DMD
disease progression.
In humans, mutations in α7-integrin or altered expression have
been associated with a range of congenital myopathies in patients
positive for other DGC components.94,95 Histological analyses of
α7-integrin deficient patients showed mild myopathy, including
myofiber size variation and centralized nuclei, but little or no
myofiber degeneration. Some patients were identified as having
primary mutations in the α7-integrin gene itself,94 while others
lacked protein but had no mutation, suggesting that α7-integrin
deficiency may be secondary.95 Overall, the myopathies asso-
ciated with α7-integrin deficiency demonstrate the importance,
and non-redundancy, of structural proteins outside the DGC in
maintaining myofiber integrity.
Myogenic differentiation 1 (mdx/Myod1−/−)
MYOD1 was the first muscle-specific transcription factor to be
identified.96 A helix loop helix protein, MYOD1 heterodimerizes
with E-proteins to bind to and activate muscle-specific genes.97 It
is a member of a family of developmentally regulated genes
encoding myogenic transcription factors that includes myogenic
factor 5 (Myf5), myogenin (Myog), and myogenic factor 6 (also
known as Herculin and Mrf4). While the studies described above
investigated the role of structural components of muscle in DMD,
a separate approach has been to assay the role of myogenic
progenitors in the regeneration response in DMD through the
activity of the bHLH family of proteins.
The Myod1tm1Jae single knockout mouse (Myod1−/−) was
created to characterize the role of Myod1 in muscle development
and regeneration.98 As described above, Myod1 knockouts alone
have no apparent phenotype, due to overlapping function and
compensation by another bHLH transcription factor, Myf5.
The mdx/Myod1−/− double knockout mouse99,100 lacks dystro-
phin and the myogenic regulator Myod1, which is crucial for
proliferation and differentiation of skeletal muscle progenitors
during regeneration.96 Double mdx/Myod1−/− knockouts have
significantly increased dystrophic disease severity. Animals have
markedly reduced muscle mass and myofiber cross sectional area,
develop kyphosis by 3–5 months of age and die prematurely at
12 months of age. Consistent with the role of MyoD1 as a
regulator of myogenesis, satellite cells from mdx/Myod1−/− have
impaired myogenic capacity. Despite a greater than 2-fold
increase compared to mdx animals, satellite cells from double
knockout animals are unable to contribute to new myofibers due
to an increased propensity for self-renewal instead of differentia-
tion. Accordingly, mdx/Myod1−/− mice have markedly reduced
regeneration capacity following injury, with high numbers of
mononuclear cells but limited myofiber formation.100 Overall, the
mdx/Myod1−/− double knockout mouse model was instrumental
in showing the critical role of Myod1 in adult muscle regeneration,
as well as the requirement for satellite cells in response to muscle
injury
Intriguingly, despite the fact that MYOD1 is not expressed in the
heart, mdx/Myod1−/− mutants developed progressive cardiomyo-
pathy.99 Hearts become hypertrophic by 5 months of age, with
increases in ventricular diameter as well as regions of cardiomyo-
cyte hypertrophy predominantly in the LV. By 10 months of age
fibrosis in hearts becomes apparent, with surviving animals at
12 months displaying extensive fibrotic regions confined primarily
to the LV. Functional defects have been noted by echocardiology.
These heart phenotypes, despite the lack of MYOD1 involvement
in the heart, demonstrate that the systemic changes induced by
skeletal muscle myopathy contribute to subsequent
cardiomyopathy.
MYOD1 mutations or alterations in protein expression do not
occur in human DMD. In addition, human cases of MYOD1
mutations are rare, likely due to a requirement for this key
transcription factor during development. While Myod−/− mice are
viable, MYOD1 loss of function mutations in humans are
associated with perinatal lethal fetal akinesia, which is character-
ized by lack of fetal movement, growth retardation and facial
defects. The three affected infants studied also had diaphragm
and kidney abnormalities, and died shortly after birth due to
hypoxic events. Histological analyses were not performed. These
early phenotypes underscore the importance of MYOD1 in
development, and, in these cases, the inability of MYF5 to
compensate for MYOD1 function in humans. In summary, its
involvement in human disorders underscores the critical role of
MYOD1 in the regulation of the muscle progenitor regenerative
response, but not directly in the pathogenesis of DMD.
Putative cytidine monophosphate-N-acetylneuraminic acid
hydroxylase-like protein (mdx/Cmah−/−)
Key cell-surface glycans with variable numbers of carbohydrates
mediate extracellular signaling.101 Sialic acids are a class of
monosaccharides expressed on the terminal ends of many glycan
structures. In mammals, these acids take the form of N-
acetylneuraminic acid (Neu5Ac) and N-glycolylneuraminic acid
(Neu5Gc).102 Glycans on skeletal and cardiac muscle in mice
comprise a 50:50 mixture of Neu5Gc and Neu5Ac, whereas
humans lack Neu5Gc completely. This difference is caused by a
human-specific deletion in the gene putative cytidine monopho-
sphate-N-acetylneuraminic acid hydroxylase-like protein (Cmah),
which encodes CMP-Neu5Ac hydroxylase, the enzyme that
catalyzes the synthesis of Neu5Gc. In order to mimic this deletion,
an inactivating deletion was introduced in the mouse Cmah gene.
Single Cmahtm1Avr knockouts (Cmah−/−) have a “humanized”
inactivation of CMAH. They exhibit elevated levels of the precursor
N-acetylneuraminic acid and sialic acid O acetylation, as well as
some behavioral, metabolic and wound healing deficits, but no
muscle defects.103
When crossed with the mdx mouse to produce the mdx/Cmah−/
− double knockout, the humanizing Cmah mutation leads to a
synergistic enhancement of all the classic symptoms of DMD.101
Compared to mdx controls, mdx/Cmah−/− mice have significantly
increased fibrosis in the quadriceps and gastrocnemius at 6 weeks,
the diaphragm at 6 months and, most notably, in the heart at
3 months of age. By 8 months of age, mdx/Cmah−/− mouse show
70% reduction in speed and 88% reduction in peak force of
diaphragm muscle strength compared to mdx controls. Impor-
tantly, cardiac defects are also observed. Hearts show early
necrotic foci by 3 months of age, as well as a 60% reduction in
peak force of cardiac trabeculae at 6 Hz compared to WT hearts,
though no cardiomyopathy has been noted. Finally, lifespan is
significantly reduced, with over half of mdx/Cmah−/− mice dying
by 11 months of age. Although the mice did not manifest the
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DCM from which DMD patients die, overall, this mouse model set
a successful precedent for “humanization” as an approach to more
closely approximate the human disease.
Telomerase RNA component (mdx4cv/mTR−/−)
Although mice have much shorter lifespans than humans (~2 vs.
~75 years), they have much longer telomeres, the protective caps
at the ends of chromosomes, that do not shorten appreciably
during aging.104 Mouse strains vary both in length and number of
short telomeres.105 The reason for the difference between mice
and humans remains unknown.
The length of telomeres dictates replicative lifespan of cells,
known as the Hayflick limit. Telomere length is maintained by the
enzyme telomerase, which is comprised of the protein telomerase
reverse transcriptase and the telomerase RNA component (TERC
or mTR). Single gene knockout of mTR leads to ubiquitous
telomere shortening, which is initiated in the germ line and
propagated to subsequent generations at each mating. The
Terctm1Rdp knockout (mTR−/−) manifests a global premature aging
phenotype by the fourth generation, mTRG4, including DCM. At
second generation, mTRG2, the mTR knockout has no
phenotype.106,107
To test if “humanization” of telomere lengths could recapitulate
the DMD disease phenotype, the mdx4cv/mTRG2 double knockout
mouse was generated (Fig. 2).108 By the second generation, when
telomeres are somewhat shortened in all tissues, mdx4cv/mTRG2
exhibited a skeletal muscle phenotype resembling DMD including
progressive limb and diaphragm muscle wasting, kyphosis,
increased fibrosis and calcium deposits, loss of strength. Myoblasts
isolated from these mice exhibit shortened telomeres compared
to cells in the spleen and testes, as well as compared to their
counterparts in mdx4cv/mTRHet controls.108 This telomere short-
ening led to a defect in muscle regenerative response due to
progressive exhaustion and premature depletion of the reservoir
of MuSCs necessary to fuel myofiber repair. Importantly, like DMD
patients, in mdx4cv/mTRG2 mice progressive DCM is the cause of
premature death,109 which is not the case for mice in which the
mdx mutation was bred to different mouse backgrounds.61
mdx4cv/mTRG2 mice show decreased cardiac output, progressive
fibrosis, and cardiac contractile and conductance dysfunction
leading to shortened life span due to heart failure. Specifically, LV
enlargement is evident, accompanied by anatomic features of
eccentric hypertrophy, including dilation of the ventricular
chambers and thinning of the myocardial wall as in late stage
DMD patients.59,110
The significance of telomere shortening is underscored by the
finding that cardiomyocytes of DMD patients have 50% shorter
telomeres than cardiomyocytes of unaffected individuals or the
Mdx4Cv mTRHet
X
Mdx4Cv/4Cv/mTRHet
X
Mdx4Cv/mTRKO Mdx4Cv/4Cv/mTRKO
Het
G1
G2
X
Telomere length
Mdx4Cv/mTRHet Mdx4Cv/4Cv
X
Mdx4Cv/mTRHet
Mdx4Cv/mTRKO Mdx4Cv/4Cv/mTRKO
X
Telomere Chromosome
Fig. 2 Crossing scheme for generation of the mdx4cv/mTRG2 model of Duchenne Muscular Dystrophy. Breeding begins with an initial cross of a
male mdx4cv animal with a female mTRHet heterozygote, both of which are available live. The male progeny of this cross are bred with female
mdx4cv/4cv animals. It should be noted that because the dystrophin gene is X-linked, males are inherently hemizygous while females are
homozygous. Progeny of the mdx4cv/mTRHet x mdx4cv/4cv cross are denoted as “Het”. Male Het animals are heterozygous for the mTR mutation
and have the mdx4cv mutation on the X-chromosome. Given the one functional copy of Terc (mTR), Hets with normal telomere lengths are
used as controls. To create the first generation of mdx4cv/mTRKO (designated as mdx4cv/mTRG1) animals with shortened telomeres, inter-cousin
breeding of mdx4cv/mTRHet is performed to avoid genetic drift.108,109 Finally, mdx4cv/mTRG1 animals are crossed, again through inter-cousin
breeding, to generate the second generation mdx4cv/mTRG2 animals. mdx4cv/mTRG2 animals have “humanized” telomere lengths that allow the
full penetrance of skeletal and cardiac muscle phenotypes
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cells in the heart that do not require dystrophin for function.109
Moreover, the cardiac dysfunction evident by electrocardiogram,
ECHO and MRI studies in the mdx4cv/mTRG2 mouse model reflects
the reduced systolic function reported for DMD patients using
such measures.111 Further, telomere shortening, which is known
to occur normally during aging in human skeletal myo-
blasts,108,112,113 is also a known feature of DMD muscle cells,
which show a diminished proliferative capacity and 14-fold
greater shortening in patients compared to healthy controls.114–
116 These findings together with the synergistic effect of telomere
shortening in the mdx4cv/mTRG2 mouse model implicates telomere
length in the progression of DMD and suggests that DMD is a
disorder of premature cardiovascular and muscle aging. Further,
these studies raise the possibility that mice are protected
from human diseases such as DMD by the length of their
telomeres. Upon comparison with other available mouse models,
the mdx4cv/mTRG2 mouse model appears to most closely
approximate the human skeletal and cardiac muscle phenotypes
of DMD.
FUTURE DIRECTIONS
With the development of new therapies for DMD on the horizon
there is a greater demand to test their efficacy in both muscle and
heart. Since the generation of the original mdx mouse, which
manifests only a mild phenotype, many mouse models have
arisen over the years to better recapitulate the disease. Many of
these models hinge on additive effects of either structural, or
myogenic gene knockouts that are not present in the human
disease in order to increase the severity of the phenotype. As a
result, the mdx model, for all its caveats, is still by far the most
widely used.
The years of extensive research in the mdx mouse and
subsequent double knockout models have vastly increased our
Fig. 3 mdx4cv/mTRG2 animal model faithfully recapitulates the skeletal and the cardiac phenotype of DMD. Molecular and functional
characterization of skeletal muscle and cardiac phenotypes in the mdx4cv/mTRG2 double knockout mouse. Overall, mdx4cv/mTRG2 exhibited
decreased life span. In the skeletal muscle, mdx4cv/mTRG2 exhibited decreased exercise capacity, decreased muscle strength, histological
evidence of muscular dystrophy, and kyphosis. In the heart, mdx4cv/mTRG2 displayed cardiac dysfunction as measured by MRI, histology, ECHO,
ECG, and electron microscopy. Figure adapted from prior mdx4cv/mTRG2 studies108,109
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understanding of the skeletal muscle component of the disease.
The utrophin mdx/utr−/− knockout demonstrated the compensa-
tory role of utrophin, a developmental homolog to dystrophin that
is upregulated in many DMD patients. Also targeting the DGC, the
α-dystrobrevin mdx/dtna−/− double knockout showed the impor-
tance of the signaling component of this structural complex, in
particular the role of nNOS localization. Focusing on a different
sarcolemmal complex, the α7-integrinmdx/α7−/− double knockout
showed the importance of non-DGC elements. Overexpression of
α7-integrin decreased the severity of the dystrophy seen in mdx/
Utrn−/− animals, while mdx/α7−/− animals had more severe
skeletal muscle and some cardiac deficits. At the satellite cell
level, the mdx/Myod1−/− knockout demonstrated not only the
importance of MyoD1 in adult muscle regeneration, but also the
critical role of satellite cells and their progeny in disease
progression. Finally, the mdx/Cmah−/− and mdx4cv/mTRG2 double
knockout models established the importance of “humanization” of
themdx model. “Humanization” strategies have been shown to act
synergistically with other specific disease mutations, such as
Werner and ataxia-telangiectasia syndromes117,118 in order to
better recapitulate a number of human conditions, including
cancer, inflammation and infectious disease. The mdx/Cmah−/−
showed that eliminating certain mouse-specific glycan modifica-
tions, which occur on many proteins in the DGC and are crucial for
signaling, unmasks more severe skeletal muscle and cardiac
phenotypes similar to human. Most recently, the mdx4cv/mTRG2
demonstrated that species-specific differences in telomere length
account for differences in the regenerative capacity of satellite
cells from mdx animals vs. humans. In addition, humanization of
telomere length uncovered premature telomere shortening in
cardiomyocytes as a hitherto unknown characteristic of DMD.
Nevertheless, despite the heroic fundamental insights into DMD
disease progression paved by these many mouse models, there
are still few tenable therapies. Instead, increased lifespan in DMD
patients has been primarily due to advancements in cardiac and
respiratory support, which only treat symptoms of the disease.
Gene editing strategies, including exon skipping,71,119–121 delivery
of mini-dystrophin122 and direct editing of the genome through
CRISPR,123–125 show promise in restoring dystrophin expression
and skeletal muscle strength in mdx animals (see McGreevy 2015
for review).126 However, gene-editing constructs must be tailored
for the particular mutation of each patient, and, to date, have
limited penetrance, especially in the heart. If systematic develop-
ment of more modular therapies is to progress, the field will
require a mouse model more similar to the mdx model. Even with
improved delivery of promising strategies like gene editing,
testing must be done in mice with the full spectrum of DMD
pathology. In particular, therapies that address the progressive
DCM in DMD necessitate an animal model with both functional, as
well as cellular heart defects on par with the human disease. To
ensure that our therapies continue to become more effective and
sophisticated, so too must our disease models. To date mdx4cv/
mTRG2 appears to most closely recapitulate both the skeletal
muscle as well as the cardiac DMD phenotypes (Fig. 3), but is
cumbersome to generate due to the multiple genotypes that must
be maintained. We are therefore pleased to report that the
Jackson Laboratories is now providing these mice at the cost of
the mdx mouse to researchers worldwide.
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